NZ608343A - Anti-angiogenic agents and methods of use - Google Patents

Anti-angiogenic agents and methods of use

Info

Publication number
NZ608343A
NZ608343A NZ608343A NZ60834308A NZ608343A NZ 608343 A NZ608343 A NZ 608343A NZ 608343 A NZ608343 A NZ 608343A NZ 60834308 A NZ60834308 A NZ 60834308A NZ 608343 A NZ608343 A NZ 608343A
Authority
NZ
New Zealand
Prior art keywords
disease
methods
human
angiogenic agents
disorder
Prior art date
Application number
NZ608343A
Inventor
Qu Zhican
Mittal Roy Anshu
Ananthan Subramaniam
Original Assignee
Southern Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Southern Res Inst filed Critical Southern Res Inst
Publication of NZ608343A publication Critical patent/NZ608343A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Disclosed herein is the use of terfenadine in the manufacture of a medicament for inhibiting the growth or metastasis of a human breast or human ovarian tumor, for treating a disease or disorder associated with angiogenesis in a human in need thereof, wherein the disease or disorder is selected from the group consisting of restenosis, rheumatoid arthritis, Crohn’s disease, diabetic retinopathy, psoriasis, endometriosis, macular degeneration, neovascular glaucoma, and adiposity.
NZ608343A 2007-04-13 2008-04-14 Anti-angiogenic agents and methods of use NZ608343A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91164507P 2007-04-13 2007-04-13
NZ592289A NZ592289A (en) 2007-04-13 2008-04-14 Anti-Angiogenic Agents and Methods of Use

Publications (1)

Publication Number Publication Date
NZ608343A true NZ608343A (en) 2014-09-26

Family

ID=40351375

Family Applications (4)

Application Number Title Priority Date Filing Date
NZ608343A NZ608343A (en) 2007-04-13 2008-04-14 Anti-angiogenic agents and methods of use
NZ580495A NZ580495A (en) 2007-04-13 2008-04-14 Use of anti-angiogenic agents and methods of use, particulary amiodarone for inhibiting or reducing angiogenesis
NZ592289A NZ592289A (en) 2007-04-13 2008-04-14 Anti-Angiogenic Agents and Methods of Use
NZ581134A NZ581134A (en) 2007-04-13 2008-04-14 Use of anti-angiogenic agents and methods of use, in particular bithionol for inhibiting or reducing angiogenesis

Family Applications After (3)

Application Number Title Priority Date Filing Date
NZ580495A NZ580495A (en) 2007-04-13 2008-04-14 Use of anti-angiogenic agents and methods of use, particulary amiodarone for inhibiting or reducing angiogenesis
NZ592289A NZ592289A (en) 2007-04-13 2008-04-14 Anti-Angiogenic Agents and Methods of Use
NZ581134A NZ581134A (en) 2007-04-13 2008-04-14 Use of anti-angiogenic agents and methods of use, in particular bithionol for inhibiting or reducing angiogenesis

Country Status (13)

Country Link
US (4) US8367737B2 (en)
EP (6) EP2420230A3 (en)
JP (4) JP5291700B2 (en)
KR (1) KR101519028B1 (en)
CN (3) CN101940571A (en)
AU (2) AU2008287285B2 (en)
BR (2) BRPI0810621A2 (en)
CA (4) CA2681267C (en)
EA (2) EA200970948A1 (en)
ES (3) ES2534589T3 (en)
MX (1) MX2009011068A (en)
NZ (4) NZ608343A (en)
WO (1) WO2009023299A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101642451B (en) * 2008-08-08 2013-04-24 湘北威尔曼制药股份有限公司 New application of amiodarone and derivatives thereof
US8865901B2 (en) 2009-10-02 2014-10-21 Fred Hutchinson Cancer Research Center Gain-of-function Bcl-2 inhibitors
WO2011041731A2 (en) * 2009-10-02 2011-04-07 Fred Hutchinson Cancer Research Center Method of inhibiting bcl-2-related survival proteins
US20130143869A1 (en) * 2010-07-16 2013-06-06 Merz Pharma Gmbh & Co. Kgaa Use of a cationic amphiphilic drug for the preparation of a formulation for the reduction of subcutaneous adipose tissue
EP2758403B1 (en) 2011-09-21 2016-04-27 Inception Orion, Inc. Tricyclic compounds useful as neurogenic and neuroprotective agents
US20140005260A1 (en) * 2012-06-28 2014-01-02 Tri-Service General Hospital Method for inhibiting cancer metastasis by amiodarone
CN103848985B (en) * 2012-11-30 2018-03-02 杨子剑 Noval chemical compound and preparation method and purposes containing Sutent analog structure
WO2015200214A1 (en) * 2014-06-23 2015-12-30 Wisconsin Alumni Research Foundation Use of inhibitors of acid sphingomyelinase to treat acquired and inherited retinal degenerations
WO2017070538A1 (en) * 2015-10-21 2017-04-27 Keck Graduate Institute Of Applied Life Sciences Inhibition of multiple pathogenic agents using bithionol
WO2017177037A1 (en) 2016-04-06 2017-10-12 University Of Virginia Patent Foundation Compositions and methods for treating cancer
CN115708821B (en) * 2022-11-30 2024-07-26 中国海洋大学 Application of marine fungus source compound in preparation of anti-tumor angiogenesis drugs

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3248401A (en) 1966-04-26 Diethylaminoe hoxybenzoyl benzofurans
US2645640A (en) 1953-07-14 Phenthiazine derivatives
US2849494A (en) 1956-05-17 1958-08-26 Monsanto Chemicals 2, 2'-thiobis
US2860138A (en) 1956-11-21 1958-11-11 Schering Corp Carbamate esters of hydroxyalkyl piperazino alkyl phenothiazines
NL110232C (en) 1958-12-06
US3506720A (en) 1963-02-22 1970-04-14 Geigy Chem Corp Halogenated hydroxy-diphenyl ethers
US3878217A (en) 1972-01-28 1975-04-15 Richardson Merrell Inc Alpha-aryl-4-substituted piperidinoalkanol derivatives
US4254129A (en) 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
US4485107A (en) 1982-11-01 1984-11-27 Janssen Pharmaceutica N.V. [[Bis(aryl)methylene]-1-piperidinyl]alkyl-pyrimidinones
US4533665A (en) 1983-07-27 1985-08-06 Janssen Pharmaceutica [[Bis(aryl)methylene]-1-piperidinyl]alkyl-pyrimidinones
CA2065375A1 (en) * 1989-08-21 1991-02-22 Richard J. Sharpe Method and composition for the treatment of cutaneous, ocular, and mucosal hypersensitivity, inflammation, and hyperproliferative conditions using topical preparations of serotonin antagonists
DK0533833T3 (en) 1990-06-13 1996-04-22 Arnold Glazier Phosphorus prodrugs
WO1992002511A1 (en) 1990-08-10 1992-02-20 Bristol-Myers Squibb Company Novel process for the preparation of nucleotides
EP0547172A1 (en) 1990-09-04 1993-06-23 Miles Inc. REGULATION OF T-CELL PROLIFERATION VIA A NOVEL 5HT1a RECEPTOR
CA2098198A1 (en) * 1990-12-18 1992-06-18 Ann Christie King Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
ATE363283T1 (en) * 1992-08-03 2007-06-15 Sepracor Inc TERFENADINE CARBOXYLATE AND THE TREATMENT OF SKIN IRRITATION
ATE199906T1 (en) 1993-06-29 2001-04-15 Mitsubishi Chem Corp PHOSPHONATE NUCLEOTIDE ESTER DERIVATIVES
JP4063868B2 (en) * 1995-02-28 2008-03-19 ザ ジレット カンパニー Use of angiogenesis inhibitors to inhibit hair growth
US5635351A (en) * 1995-03-14 1997-06-03 The Regents Of The University Of California Genetic gain and loss in gliomas
US5977061A (en) 1995-04-21 1999-11-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic N6 - substituted nucleotide analagues and their use
TW369536B (en) 1996-01-18 1999-09-11 Mitsubishi Chem Corp Phosphonate nucleotide compounds
JP4369994B2 (en) * 1996-02-29 2009-11-25 ノバルティス アクチエンゲゼルシャフト AT for lowering apoptosis 1 Receptor antagonist
US5801564A (en) 1996-06-28 1998-09-01 Symbios, Inc. Reduced skew differential receiver
JP4033494B2 (en) 1996-07-26 2008-01-16 ギリヤド サイエンシーズ， インコーポレイテッド Nucleotide analogs
CN1088459C (en) * 1996-10-04 2002-07-31 诺沃挪第克公司 1,4-disubstituted piperazines
US6284748B1 (en) 1997-03-07 2001-09-04 Metabasis Therapeutics, Inc. Purine inhibitors of fructose 1,6-bisphosphatase
EP1119252A4 (en) * 1998-08-21 2004-03-03 Childrens Medical Center Use of melanin for inhibition of angiogenesis and macular degeneration
AU1549500A (en) * 1998-12-02 2000-06-19 Novo Nordisk A/S Use of n-substituted azaheterocyclic compounds for the manufacture of a pharmaceutical composition for the treatment of indications related to angiogenesis
MXPA01007038A (en) 1999-01-13 2002-07-30 Genentech Inc Serine protease inhibitors.
AU2864100A (en) * 1999-02-01 2000-08-18 Cytovia, Inc. Methods of identifying therapeutically effective antineoplastic agents with cultured cells having intact cell membranes and corresponding products
KR20020093824A (en) 2000-02-29 2002-12-16 미쯔비시 웰 파마 가부시키가이샤 Phosphonate nucleotide compound
FR2815541B1 (en) * 2000-10-24 2008-02-29 Lipha USE OF PERICYTE APOPTOSIS INHIBITORS FOR THE TREATMENT AND / OR PREVENTION OF DIABETIC RETINOPATHY
IL139975A0 (en) * 2000-11-29 2002-02-10 Univ Ramot Anti proliferative drugs
EP1360180A1 (en) * 2001-01-19 2003-11-12 Cytokinetics, Inc. Phenothiazine kinesin inhibitors
MY141789A (en) 2001-01-19 2010-06-30 Lg Chem Investment Ltd Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same.
WO2002060375A2 (en) 2001-01-29 2002-08-08 Insight Strategy And Marketing Ltd Diphenyl ether derivatives and their uses as heparanase inhibitors
US20040072824A1 (en) * 2001-06-01 2004-04-15 Adam Telerman Methods and compositions for the treatment of cancer
JP4393863B2 (en) * 2001-06-18 2010-01-06 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド Optic nerve cell protective agent
US20040121981A1 (en) * 2001-11-21 2004-06-24 Glycogenesys, Inc. Method for controlling angiogenesis in animals
DE10206941A1 (en) 2002-02-19 2003-09-25 Goetz Nowak New drugs
CN1674879A (en) 2002-06-17 2005-09-28 费城健康与教育公司 Immunomodulation and effect on cell processes relating to serotonin family receptors and the blood-brain barrier
JP2006506442A (en) * 2002-07-09 2006-02-23 ポイント セラピューティクス， インコーポレイテッド Boroproline compound combination therapy
US8268352B2 (en) 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
FR2849382A1 (en) 2002-12-26 2004-07-02 Urogene USE OF THE HTR2B GENE FOR THE TREATMENT OF PROSTATE CANCER
MXPA05008649A (en) * 2003-02-14 2005-11-23 Combinatorx Inc Combination therapy for the treatment of immunoinflammatory disorders.
WO2004080445A1 (en) * 2003-03-12 2004-09-23 Molecular Engines Laboratories Sa Methods and compositions for the treatment of cancer
JP2007500231A (en) * 2003-05-23 2007-01-11 コンビナトアールエックス インコーポレーティッド Combination treatment to treat neoplasms
SA04250283B1 (en) * 2003-09-26 2008-05-26 سولفاي فارماسيتيكالز جي أم بي أتش Derivatives of amidomethy1-substituted1-(carboxyalkyl)-cyclopentylcarbonylamino-benzazepine-N-acetic acid
WO2005060951A2 (en) * 2003-12-19 2005-07-07 Bionaut Pharmaceuticals, Inc. Anti-neoplastic agents, combination therapies and related methods
US7381401B2 (en) * 2004-01-08 2008-06-03 The University Of Chicago T cell anergy is reversed by active Ras and regulated by diacylglycerol kinase
CN1562930A (en) * 2004-03-31 2005-01-12 深圳中药及天然药物研究中心 Preparation of ramification of polyhalo-substitution diphenyl ethers and medication application
US20060009506A1 (en) * 2004-07-09 2006-01-12 Odyssey Thera, Inc. Drugs for the treatment of neoplastic disorders
KR20060130406A (en) * 2005-06-14 2006-12-19 이제호 A novel inhibitor of angiogenesis, cell proliferation and cellular invasion by targeting ras signalling pathway
US20060287301A1 (en) * 2005-06-17 2006-12-21 Mcnair Douglas Novel formulations for phenothiazines, including fluphenazine and its derivatives
US20100080843A1 (en) * 2005-06-30 2010-04-01 The Research Foundation of the State University Of New York at Albany Natural and synthetic sulfur and selenium analogs and polymer conjugated forms thereof for the modulation of angiogenesis
WO2007022273A2 (en) * 2005-08-15 2007-02-22 The Regents Of The University Of California Vegf-activated fas ligands
JP2007084508A (en) * 2005-09-26 2007-04-05 Shiseido Co Ltd New vascular endothelial growth factor expression inhibitor
EA200800971A1 (en) * 2005-09-29 2008-08-29 Арена Фармасьютикалз, Инк. PHARMACEUTICAL COMPOSITIONS OF THE MODULATOR OF 5-NTRECEPTORS OF SEROTONIN, USEFUL IN THE TREATMENT OF RELATED DISORDERS
JP4492810B2 (en) 2006-02-14 2010-06-30 ソニー株式会社 Attenuation adjustment circuit, optical disc drive apparatus, attenuation adjustment method, and address information acquisition method
US20070225238A1 (en) 2006-02-24 2007-09-27 Charlier Henry A Jr Inhibitors of carbonyl reductase for treatment using anthracyclines
GB0701170D0 (en) 2007-01-22 2007-02-28 Imp Innovations Ltd Compositions and uses thereof

Also Published As

Publication number Publication date
ES2534345T3 (en) 2015-04-21
EA019919B1 (en) 2014-07-30
CA2874595A1 (en) 2009-02-19
EP2420238A2 (en) 2012-02-22
EA200970947A1 (en) 2010-04-30
AU2008287285A1 (en) 2009-02-19
EP2420238A3 (en) 2012-03-07
CA2826272A1 (en) 2009-02-19
NZ592289A (en) 2013-03-28
BRPI0810621A2 (en) 2017-06-06
JP2010523719A (en) 2010-07-15
EP2420239B1 (en) 2015-01-14
KR20090130100A (en) 2009-12-17
CN101801386B (en) 2013-09-04
EP2420236B1 (en) 2015-01-14
AU2008287285B2 (en) 2013-05-16
US20130123240A1 (en) 2013-05-16
CN101940571A (en) 2011-01-12
KR101519028B1 (en) 2015-05-11
CA2681267C (en) 2013-11-19
JP5291700B2 (en) 2013-09-18
ES2534589T3 (en) 2015-04-24
CA2683316A1 (en) 2009-02-19
EP2139325A2 (en) 2010-01-06
CN101801386A (en) 2010-08-11
US20100120745A1 (en) 2010-05-13
JP2010159265A (en) 2010-07-22
US20100204338A1 (en) 2010-08-12
WO2009023299A3 (en) 2009-05-22
EP2139325A4 (en) 2011-09-14
EP2161023A3 (en) 2010-12-29
EP2420230A2 (en) 2012-02-22
CN102772415A (en) 2012-11-14
EP2420236A3 (en) 2012-06-27
EP2420239A2 (en) 2012-02-22
EP2139325B1 (en) 2015-01-14
NZ581134A (en) 2011-04-29
US8367737B2 (en) 2013-02-05
WO2009023299A2 (en) 2009-02-19
AU2009238237A1 (en) 2009-12-03
ES2534588T3 (en) 2015-04-24
AU2009238237B2 (en) 2013-02-07
EA200970948A1 (en) 2010-08-30
EP2420239A3 (en) 2012-07-11
NZ580495A (en) 2011-05-27
EP2420236A2 (en) 2012-02-22
WO2009023299A9 (en) 2009-04-02
MX2009011068A (en) 2010-01-13
EP2420230A3 (en) 2012-06-27
JP2015003914A (en) 2015-01-08
US20150164873A1 (en) 2015-06-18
JP2013166802A (en) 2013-08-29
CA2681267A1 (en) 2009-02-19
EP2161023A2 (en) 2010-03-10
BRPI0810897A2 (en) 2016-07-26

Similar Documents

Publication Publication Date Title
NZ608343A (en) Anti-angiogenic agents and methods of use
UA107782C2 (en) Fgf-r4 receptor-specific antagonist
HK1137146A1 (en) Pharmaceutical compositions comprising activin-actriia antagonists for use in preventing or treating breast cancer metastasis or breast cancer related bone loss
NZ592132A (en) Composition comprising nanoparticles of docitaxel and a citrate
MX2010009156A (en) Combination therapy 238.
NZ584848A (en) Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof
HK1139030A1 (en) Surgical articles for treating pelvic conditions
MX338324B (en) Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy.
UA92317C2 (en) Carboline derivatives useful in the inhibition of angiogenesis
MX2017010336A (en) Integrin beta7 antagonists and methods of treating crohn's disease.
MX2016000131A (en) Docetaxel polymeric nanoparticles for cancer treatment.
MY151449A (en) Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
IN2012DN02826A (en)
MX2018001946A (en) High-strength steel sheet and production method for same.
HUS2300004I1 (en) 2,4,6-trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl]-benzamide for the treatment of migraine via the oral or intravenous route
MX2014005183A (en) Anti-kdr antibodies and methods of use.
MX2009009816A (en) Monoclonal antibodies for treatment of cancer.
MY175332A (en) Methods of administering beta7 integrin antagonists
MX2012001306A (en) Inhibition of tumor metastasis using bv8- or g-csf-antagonists.
MX359210B (en) Procaspase 3 activation by combination therapy.
MX2014006762A (en) Methods for treating cardiovascular disorder.
MX2023008504A (en) Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-vegf.
TN2011000319A1 (en) Substituted quinazoline compounds
MX2010008994A (en) Combination comprising paclitaxel for treating ovarian cancer.
MX2013002155A (en) Compounds for treatment of cancer.

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 14 APR 2015 BY FRASER OLD + SOHN

Effective date: 20150112

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 APR 2016 BY COMPUTER PACKAGES INC

Effective date: 20150318

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 APR 2017 BY COMPUTER PACKAGES INC

Effective date: 20160318

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 APR 2018 BY COMPUTER PACKAGES INC

Effective date: 20170318

LAPS Patent lapsed